

Remarks

Applicants thank Examiner Chang for the courtesy she extended to Mssrs. Muller, Girards, and Bachrach during the interview held on August 1, 2004. This response is filed further to that interview, and to the Office Action of September 16, 2004.


During the interview, the Examiner indicated that claims 10-21 are allowable. Therefore, Applicants elect Group I, which encompasses claims 10-21. To expedite the prosecution of this application, Applicants cancel all of the remaining claims that were pending without prejudice. New claims 101-103, which recite individual compounds exemplified in the specification that are encompassed by claims 10 and 14, are added. New claims 104-105 respectively recite a stereoisomer and a racemate of a compound of claim 10, 14, 18, 101, 102, or 103. No new matter has been introduced.

To be complete, Applicants elect N- {[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisindolin-4-yl]methyl} cyclopropyl-carboxamide (designated I-4 in the specification) as the single species to be searched. However, since the Examiner agreed during the interview that claims 10-21 are allowable, allowance of the pending claims are earnestly sought.

No fee is believed to be due for this submission. However, should any fees be required for the submission of this paper, or to avoid abandonment of this application, please charge such fees to Jones Day Deposit Account No. 503013.

Respectfully Submitted,

Date: October 18, 2004


Max Bachrach 45,479
(Reg. No.)
Jones Day
51 Louisiana Avenue, N.W.
Washington, DC 20001-2113
(202) 879-3939

For: Anthony M. Insogna (Reg. No. 35,203)
Jones Day
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 314-1200